I. Marcelli

Evaluating seltorexant as a treatment option for major depressive disorder

Seltorexant 20 mg has shown a promising antidepressant effect, particularly in patients with clinically significant insomnia, and a favorable tolerability profile, and the mixed phase-3 results, the modest effect sizes, and gaps on core symptoms of depression warrant a measured positive view, pending confirmatory data.